JNJ ▼ -1.4% - Johnson & Johnson $JNJ - Johnson & Johnson announces ERLEADA® (apalutamide) treatment before and after surgery reduces risk of recurrence or death by 62% versus surgery alone in high-risk prostate cancer 24-OCT-2026 08:55 AM ET